BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $500
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $500
BMO Capital維持Vertex Pharmicals的跑贏大盤，將目標股價上調至
BMO Capital analyst Evan Seigerman maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $480 to $500.
BMO Capital分析師埃文·塞格曼維持Vertex Pharmicals（納斯達克股票代碼：VRTX）的跑贏大盤，並將目標股價從480美元上調至500美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。